Sign inJoin waitlistJoin the waitlist

Mahasweta Gooptu

Assistant Professor of Medicine, Harvard Medical School · Mass General Brigham

Credentials: · · · · · ·

History

Mass General Brigham
Present
Harvard Medical School
Present

Hematology and Medical Oncology
SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
2016–2019
Bone Marrow Transplantation
Dana-Farber Cancer Institute
2013–2016
Albert Einstein Medical College
2010–2013
Internal Medicine
Jefferson Health Medical Education
2007–2010
Kolkata Medical College and Hospital, India
2003–2007

Research

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
New England Journal of Medicine · 2023 · 550 citations
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
Blood · 2021 · First of 27 authors · 151 citations
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes
Journal of Clinical Oncology · 2022 · 133 citations

Robert Soiffer
43 papers
John Koreth
41 papers
Joseph Antin
41 papers
Corey Cutler
39 papers
Vincent Ho
39 papers
Sarah Nikiforow
31 papers
Rizwan Romee
30 papers
Jerome Ritz
27 papers
Roman Shapiro
23 papers
Catherine Wu
17 papers
Monzr Al Malki
16 papers
BS
Brian Shaffer
12 papers

Grants

BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium
National Heart, Lung, and Blood Institute · UG1
Contact PI · $509.3K · Dana-Farber Cancer Inst
2001–2031

Clinical trials

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
Principal investigator · Completed
Dana-Farber Cancer Institute
2016–2020
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Site PI · Recruiting · Phase 3
TScan Therapeutics, Inc.
2026–2029
A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Site PI · Recruiting · Phase 1
TScan Therapeutics, Inc.
2022–2028